# A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Source: https://onco.cc/trials/nct05481151/  
OnCo record `nct05481151` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ropeginterferon alfa-2b in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting.

## Summary

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV is a phase 3 interventional study registered as NCT05481151 by PharmaEssentia, with 111 participants enrolled, started 2022-10-26 and due to reach its primary completion in 2025-06-30. Interventions recorded: P1101 (Ropeginterferon alfa-2b-njft) and Ropeginterferon alfa-2b-njft (P1101).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05481151
- Phase: 3
- Setting: A Phase IIIb, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Polycythemia Vera (PV)
- Sponsor: PharmaEssentia
- Enrolled: 111

## Sources

- ClinicalTrials.gov NCT05481151: https://clinicaltrials.gov/study/NCT05481151

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- drugs: [Ropeginterferon alfa-2b](https://onco.cc/drugs/ropeginterferon-alfa-2b/)
- companies: [PharmaEssentia](https://onco.cc/companies/pharmaessentia/)

---
JSON: https://onco.cc/api/v1/entities/nct05481151.json